The U.S. Securities and Exchange Commission (SEC) has broadened its insider trading investigation, which now includes allegations against Philip Markin. The agency claims Markin engaged in a scheme to buy shares of Pandion Therapeutics Inc. ahead of its acquisition by Merck & Co. in 2021. According to the SEC, Markin acted on information received from his cousin, Seth Markin, whose romantic partner worked as an attorney at a major law firm representing Merck. The information was deemed material and nonpublic.
Read more